Telix Pharmaceuticals
(ASX:TLX) has been working on prostate therapy TLX591 which is underpinned by clinical data obtained by researchers at Weill Cornell Medical College and collaborators.
Phase two of the data demonstrates that low, repeated doses, significantly reduce hematologic toxicity while delivering an anti-tumour response and survival benefit to men with advanced castrate-resistant metastatic prostate cancer.
The side effect profile is significantly improved through low dose, repeat dosing with the most significant adverse event being white blood cell reduction and low platelet count.
The company says 'this is a significantly more robust treatment response than reported by competitive therapeutic approaches targeting prostate-specific membrane antigen'.
Shares in Telix Pharmaceuticals
(ASX:TLX) are trading 4.52 per cent higher at 93 cents.
